Free Trial

XOMA (XOMA) Stock Price, News & Analysis

+1.72 (+6.37%)
(As of 07/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
61,823 shs
Average Volume
20,355 shs
Market Capitalization
$334.27 million
P/E Ratio
Dividend Yield
Price Target

XOMA MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
98.5% Upside
$57.00 Price Target
Short Interest
2.08% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.89mentions of XOMA in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.76) to ($1.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.09 out of 5 stars

Medical Sector

241st out of 914 stocks

Pharmaceutical Preparations Industry

108th out of 433 stocks

XOMA stock logo


XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Stock Price History

XOMA Stock News Headlines

XOMA (NASDAQ:XOMA) Stock Rating Reaffirmed by HC Wainwright
Prepare for crypto’s next bull run now
The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…
XOMA Declares Quarterly Preferred Stock Dividends
3 Crazy Good Stocks to Buy With $500 Right Now
Prepare for crypto’s next bull run now
The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…
Cracking The Code: Understanding Analyst Reviews For XOMA
Actym Therapeutics Appoints Thomas Smart as CEO
XOMA Corporation Announces Closing of Tender Offer
XOMA Declares Quarterly Preferred Stock Dividends
See More Headlines
Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$5.81 million
Book Value
$7.72 per share


Free Float
Market Cap
$314.25 million

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

XOMA Stock Analysis - Frequently Asked Questions

How have XOMA shares performed this year?

XOMA's stock was trading at $18.50 on January 1st, 2024. Since then, XOMA shares have increased by 55.2% and is now trading at $28.72.
View the best growth stocks for 2024 here

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) released its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.15. The biotechnology company had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.96 million. XOMA had a negative trailing twelve-month return on equity of 26.00% and a negative net margin of 705.23%.

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA Chief Executive Officer John Varian on John Varian has an approval rating of 73% among the company's employees.

How do I buy shares of XOMA?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK) and Uranium Energy (UEC).

This page (NASDAQ:XOMA) was last updated on 7/17/2024 by Staff

From Our Partners